NZ601255A - Anaesthetic formulation - Google Patents

Anaesthetic formulation

Info

Publication number
NZ601255A
NZ601255A NZ601255A NZ60125511A NZ601255A NZ 601255 A NZ601255 A NZ 601255A NZ 601255 A NZ601255 A NZ 601255A NZ 60125511 A NZ60125511 A NZ 60125511A NZ 601255 A NZ601255 A NZ 601255A
Authority
NZ
New Zealand
Prior art keywords
cyclodextrin
anaesthetic
neuroactive steroid
alphadolone
derivative
Prior art date
Application number
NZ601255A
Other languages
English (en)
Inventor
Benjamin James Boyd
Juliet Marguerite Goodchild
Colin Stanley Goodchild
Original Assignee
Univ Monash
Goodchild Invest Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Monash, Goodchild Invest Pty Ltd filed Critical Univ Monash
Publication of NZ601255A publication Critical patent/NZ601255A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Nanotechnology (AREA)
  • Medical Informatics (AREA)
  • Biophysics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Anesthesiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NZ601255A 2010-01-21 2011-01-19 Anaesthetic formulation NZ601255A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29724910P 2010-01-21 2010-01-21
US38531810P 2010-09-22 2010-09-22
PCT/AU2011/000050 WO2011088503A1 (en) 2010-01-21 2011-01-19 Anaesthetic formulation

Publications (1)

Publication Number Publication Date
NZ601255A true NZ601255A (en) 2013-09-27

Family

ID=44306295

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ601255A NZ601255A (en) 2010-01-21 2011-01-19 Anaesthetic formulation

Country Status (27)

Country Link
US (2) US8697678B2 (enExample)
EP (1) EP2525798B1 (enExample)
JP (1) JP5930311B2 (enExample)
KR (1) KR101747476B1 (enExample)
CN (1) CN102802635B (enExample)
AU (1) AU2011207103B2 (enExample)
BR (1) BR112012017800B1 (enExample)
CA (1) CA2786762C (enExample)
CL (1) CL2012002032A1 (enExample)
CY (1) CY1119947T1 (enExample)
DK (1) DK2525798T3 (enExample)
ES (1) ES2646829T3 (enExample)
GB (2) GB2491491B (enExample)
HR (1) HRP20171699T1 (enExample)
HU (1) HUE035441T2 (enExample)
LT (1) LT2525798T (enExample)
NO (1) NO2525798T3 (enExample)
NZ (1) NZ601255A (enExample)
PL (1) PL2525798T3 (enExample)
PT (1) PT2525798T (enExample)
RS (1) RS56576B1 (enExample)
RU (1) RU2574022C2 (enExample)
SG (1) SG181997A1 (enExample)
SI (1) SI2525798T1 (enExample)
SM (1) SMT201700518T1 (enExample)
WO (1) WO2011088503A1 (enExample)
ZA (1) ZA201205370B (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2812250T3 (es) 2005-11-28 2021-03-16 Marinus Pharmaceuticals Inc Formulaciones de ganaxolona y procedimientos para la preparación y uso de las mismas
US10478505B2 (en) 2011-09-23 2019-11-19 The Regents Of The University Of California Edible oils to enhance delivery of orally administered steroids
ES2784629T3 (es) 2011-11-29 2020-09-29 Jurox Pty Ltd Composiciones farmacéuticas inyectables estables que comprenden 2-hidroxipropil-beta-ciclodextrina y alfaxalona
SG10201606063RA (en) * 2012-01-23 2016-09-29 Sage Therapeutics Inc Neuroactive steroid formulations and methods of treating cns disorders
WO2014028398A2 (en) 2012-08-13 2014-02-20 The Regents Of The University Of California Mitigation of epileptic seizures by combination therapy using benzodiazepines and neurosteroids
RS62761B1 (sr) * 2012-08-21 2022-01-31 Sage Therapeutics Inc Alopregnanolon za lečenje refraktornog epileptičkog statusa
WO2014071449A1 (en) 2012-11-09 2014-05-15 Goodchild Investments Pty Ltd Neuroactive steroids and their use to facilitate neuroprotection
US20150313915A1 (en) * 2012-11-30 2015-11-05 The Regents Of The University Of California Anticonvulsant activity of steroids
WO2015134670A1 (en) * 2014-03-05 2015-09-11 Mingbao Zhang Deuterated ganaxolone derivatives
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
JP2018504420A (ja) * 2015-02-06 2018-02-15 マリナス ファーマシューティカルズ インコーポレイテッド 静注用ガナキソロン製剤ならびにてんかん重積状態および他の発作性障害の治療におけるその使用
AR105044A1 (es) * 2015-06-18 2017-08-30 Sage Therapeutics Inc Soluciones de esteroides neuroactivos y sus métodos de uso, recipiente
US20170038184A1 (en) 2015-08-06 2017-02-09 Charles E. Ankner Formulation delivery system
US9585867B2 (en) 2015-08-06 2017-03-07 Charles Everett Ankner Cannabinod formulation for the sedation of a human or animal
KR20180082457A (ko) * 2015-10-16 2018-07-18 마리누스 파마슈티컬스 인코포레이티드 나노입자들을 포함하는 주사용 뉴로스테로이드 제제들
PH12018501923B1 (en) 2016-03-08 2024-06-28 Sage Therapeutics Inc Neuroactive steroids, compositions, and uses thereof
KR20230050474A (ko) 2016-08-11 2023-04-14 오비드 테라퓨틱스 인크. 간질 장애의 치료를 위한 방법 및 조성물
US10391105B2 (en) 2016-09-09 2019-08-27 Marinus Pharmaceuticals Inc. Methods of treating certain depressive disorders and delirium tremens
WO2019202640A1 (ja) 2018-04-16 2019-10-24 川崎重工業株式会社 ベルトコンベヤ
US11472833B2 (en) 2018-07-03 2022-10-18 Drawbridge Pharmaceuticals Pty Ltd Neuroactive steroids and methods of preparation
US11266662B2 (en) 2018-12-07 2022-03-08 Marinus Pharmaceuticals, Inc. Ganaxolone for use in prophylaxis and treatment of postpartum depression
KR20210102936A (ko) * 2018-12-10 2021-08-20 헤일로 사이언스 엘엘씨 안정적인 마취제 제제 및 관련 복용량 형태
EP4009982A4 (en) 2019-08-05 2023-08-09 Marinus Pharmaceuticals, Inc. GANAXOLONE FOR USE IN TREATMENT OF STATUS EPILEPTICUS
AU2020395254B2 (en) 2019-12-06 2026-04-02 Marinus Pharmaceuticals, Inc. Ganaxolone for use in treating tuberous sclerosis complex
CN115103591B (zh) 2019-12-27 2026-06-19 度勒科特公司 结晶性和液体结晶性25-羟基-胆甾-5-烯-3-硫酸钠及其制备方法
US11969434B1 (en) 2022-08-29 2024-04-30 Lipocine Inc. Oral allopregnanolone compositions and methods of use
US12186327B2 (en) 2022-08-29 2025-01-07 Lipocine Inc. Oral allopregnanolone compositions and methods of use

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE100712T1 (de) * 1989-05-24 1994-02-15 Innovet Inc Hypoallergene anaesthesierende/hypnotische steroide arzneizubereitung.
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
WO1993017711A1 (en) 1992-03-11 1993-09-16 Australian Commercial Research & Development Limited New cyclodextrins and new formulated drugs
US5472954A (en) * 1992-07-14 1995-12-05 Cyclops H.F. Cyclodextrin complexation
JP4227675B2 (ja) * 1996-10-25 2009-02-18 康武 日地 神経毒軽減麻酔剤
AUPQ633900A0 (en) 2000-03-20 2000-04-15 Jurox Pty Ltd Anaesthetic composition
RU2288921C2 (ru) * 2000-12-19 2006-12-10 Калифорниа Инститьют оф Текнолоджи Композиции, содержащие комплексы включения
EP1383445A4 (en) * 2001-03-20 2005-04-13 Cydex Inc FORMULATIONS WITH PROPOFOL AND A SULFOALKYL ETHER CYCLODEXTRIN
US7034013B2 (en) 2001-03-20 2006-04-25 Cydex, Inc. Formulations containing propofol and a sulfoalkyl ether cyclodextrin
IL152575A (en) * 2002-10-31 2008-12-29 Transpharma Medical Ltd A skin-to-skin transmission system of water-insoluble drugs
ES2812250T3 (es) * 2005-11-28 2021-03-16 Marinus Pharmaceuticals Inc Formulaciones de ganaxolona y procedimientos para la preparación y uso de las mismas

Also Published As

Publication number Publication date
AU2011207103A1 (en) 2012-07-26
HK1169031A1 (en) 2013-01-18
RU2574022C2 (ru) 2016-01-27
PL2525798T3 (pl) 2018-05-30
US8975245B2 (en) 2015-03-10
US20140066417A1 (en) 2014-03-06
HUE035441T2 (en) 2018-05-02
CY1119947T1 (el) 2018-12-12
BR112012017800A2 (en) 2018-07-10
DK2525798T3 (da) 2017-11-20
US8697678B2 (en) 2014-04-15
HRP20171699T1 (hr) 2018-01-26
SI2525798T1 (en) 2018-01-31
EP2525798A4 (en) 2014-02-19
GB2491491B (en) 2014-07-30
PT2525798T (pt) 2017-11-15
SMT201700518T1 (it) 2018-01-11
ES2646829T3 (es) 2017-12-18
GB2484244A (en) 2012-04-04
GB2484244B (en) 2012-10-31
LT2525798T (lt) 2018-01-10
ZA201205370B (en) 2013-09-25
KR20120136347A (ko) 2012-12-18
BR112012017800B1 (pt) 2020-12-08
US20120316146A1 (en) 2012-12-13
RU2012134321A (ru) 2014-02-27
JP5930311B2 (ja) 2016-06-08
SG181997A1 (en) 2012-08-30
WO2011088503A1 (en) 2011-07-28
GB201201842D0 (en) 2012-03-21
CL2012002032A1 (es) 2012-12-21
EP2525798B1 (en) 2017-08-09
KR101747476B1 (ko) 2017-06-14
RS56576B1 (sr) 2018-02-28
NO2525798T3 (enExample) 2018-01-06
JP2013517299A (ja) 2013-05-16
GB2491491A (en) 2012-12-05
EP2525798A1 (en) 2012-11-28
CA2786762C (en) 2017-12-05
AU2011207103B2 (en) 2013-03-21
BR112012017800A8 (pt) 2018-08-14
CN102802635A (zh) 2012-11-28
CA2786762A1 (en) 2011-07-28
CN102802635B (zh) 2014-07-30
GB201210657D0 (en) 2012-08-01

Similar Documents

Publication Publication Date Title
SMT202000008T1 (it) Formulazione di steroide neuroattivo comprendente un complesso di allopregnanolone e solfobutil eter beta-ciclodestrina
PH12015500105A1 (en) Lavatory treatment device
GB2484244A (en) Anaesthetic formulation
IN2012DN02092A (enExample)
JP2013517299A5 (enExample)
MX2020001262A (es) Compuestos de platino a base de lipido y nanoparticulas.
PH12012501619A1 (en) Synthesis of magnolol and its analogue compounds
WO2014155019A3 (fr) Composition alcoolique ou hydro-alcoolique parfumante contenant un ether aliphatique
BR112013003216A2 (pt) composições sintéticas de ácido biliar e métodos
NZ609420A (en) Fulvestrant compositions and methods of use
WO2013072768A3 (en) Synthetic derivatives of mpl and uses thereof
BR112016013194A2 (pt) Composições de higiene oral compreendendo carbonato de cálcio e sílica
BR112014010133A2 (pt) compostos pesticidas
MX360293B (es) Composiciones de perfume.
BR112012010149A2 (pt) composto de paclitaxel / esteroidal
CO6501175A2 (es) Derivados de benzotiazinas, su preparación y aplicación como fármacos
EA201300616A1 (ru) Быстро распадающиеся композиции, включающие набилон и случайным образом метилированный бета-циклодекстрин
BR112013025122A2 (pt) uso cosmético de pelo menos um composto
EA201370060A1 (ru) КЛАТРАТНЫЕ КОМПЛЕКСЫ β-ЦИКЛОДЕКСТРИНА С 1-{[6-БРОМ-1-МЕТИЛ-5-МЕТОКСИ-2-ФЕНИЛТИОМЕТИЛ-1-Н-ИНДОЛ-3-ИЛ]КАРБОНИЛ}-4-БЕНЗИЛПИПЕРАЗИНОМ, ОБЛАДАЮЩИЕ ПРОТИВОВИРУСНОЙ АКТИВНОСТЬЮ, ИХ ПОЛУЧЕНИЕ И ПРИМЕНЕНИЕ
ATE538773T1 (de) Auf prostaglandin basierende zusammensetzung und verfahren zu ihrer verwendung
MY184686A (en) Skin cleanser composition
CL2015000822A1 (es) Método de síntesis de ciclohexenonas y su uso en perfumeria
WO2014166836A8 (en) Growth hormone compound formulation
BR112012032834A2 (pt) composições aglutinantes de copolímero de acetato de vinila plastificado para manta de fio picado.
MY176755A (en) Skin cleanser composition packaged in foamer container

Legal Events

Date Code Title Description
ASS Change of ownership

Owner name: DRAWBRIDGE PHARMACEUTICALS PTY LTD, AU

Effective date: 20131024

PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 19 JAN 2016 BY CPA GLOBAL

Effective date: 20141204

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 19 JAN 2017 BY CPA GLOBAL

Effective date: 20151204

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 19 JAN 2018 BY CPA GLOBAL

Effective date: 20161210

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 19 JAN 2019 BY CPA GLOBAL

Effective date: 20171208

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 19 JAN 2020 BY CPA GLOBAL

Effective date: 20190215

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 19 JAN 2021 BY CPA GLOBAL

Effective date: 20191205

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 19 JAN 2022 BY CPA GLOBAL

Effective date: 20201203

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 19 JAN 2023 BY CPA GLOBAL

Effective date: 20220607

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 19 JAN 2024 BY AMIT SINGH

Effective date: 20230715

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 19 JAN 2025 BY FB RICE PTY LTD

Effective date: 20240708

LAPS Patent lapsed